Immunalgia Therapeutics is entering a phase I clinical trial on safety and pharma

This is a single-center, open-label, dose-escalating phase I clinical trial in healthy volunteers 18 to 60 years old. This clinical trial is designed to assess the safety, and pharmacokinetics of our drug candidate IMT504 as a potential new treatment for chronic pain.

The study will be conducted in Argentina under the regulations and approval of the National Administration of Medicines, Food and Medical Technology (ANMAT), and ICHC guidelines.